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Abstract: Glioblastomas (GBM) are the most frequent brain tumors lacking efficient treatment.
The increasingly elucidated gene targets make siRNA-based gene therapy a promising anticancer
approach, while an efficient delivery system is urgently needed. Here, polyethyleneimine (PEI)-coated
Fe3O4 nanoparticles (NPs) have been developed and applied for siRNA delivery into GBM cells to
silence repressor element 1-silencing transcription factor (REST). The prepared PEI-coated Fe3O4
NPs were characterized as magnetic nanoparticles with a positive charge, by transmission electronic
microscopy, dynamic light-scattering analysis and a magnetometer. By gel retardation assay, the
nanoparticles were found to form complexes with siRNA and the interaction proportion of NP
to siRNA was 2.8:1. The cellular uptake of NP/siRNA complexes was verified by prussian blue
staining, fluorescence labeling and flow cytometry in U-87 and U-251 GBM cells. Furthermore,
the REST silencing examined by realtime polymerase chain reaction (PCR) and Western blotting
presented significant reduction of REST in transcription and translation levels. Upon the treatment of
NP/siRNA targeting REST, the GBM cell viabilities were inhibited and the migration capacities were
repressed remarkably, analyzed by cell counting kit-8 and transwell assay separately. In this study,
we demonstrated the PEI-coated Fe3O4 nanoparticle as a vehicle for therapeutic siRNA delivery, at
an appropriate NP/siRNA weight ratio for REST silencing in GBM cells, inhibiting cell proliferation
and migration efficiently. These might represent a novel potential treatment strategy for GBM.
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1. Introduction
Glioblastomas (GBM, World Health Organization (WHO) grade IV) are the most frequent
and invasive malignant primary tumors of the central nervous system [1,2]. Currently, treatments
available for GBM patients are limited to surgery, non-specific chemotherapy and radiotherapy [3].
Despite improvements in these conventional therapies, the median survival of patients with GBM is
only approximately 15 months and only 3–5% of the patients survive more than 3 years [4]. Thus, novel
treatment strategies for GBM are needed urgently.
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Gene therapy is the delivery of therapeutic nucleic acid (including DNA, antisense
oligonucleotides and short interfering RNA (siRNA), etc.) into a patient’s cells as a drug to treat
diseases [5]. Specifically designed double-stranded siRNA could induce the specific degradation of
homologous messenger RNA, leading to gene silencing [6]. siRNA has been widely used as a research
tool for studying gene functions and investigated as a novel therapeutic strategy against various
disorders including cancers [7]. Since increasing gene targets have been elucidated and any gene can
be targeted by siRNA, siRNA-based gene therapy is considered a promising new anticancer approach.
The siRNA is easy to degrade by widely-existing Ribonuclease (RNase), and it possesses the same
negative charge as the cell membrane. Accordingly, siRNA cannot be readily taken up by cells and
efficient delivery vehicles for siRNA are critical for the delivery of therapeutic siRNA. During the
past decade, several types of nanoparticle (NP) delivery systems have been developed, including
inorganic NPs, lipid-based nanocarriers, polymeric NPs, dendrimers, solid lipid NPs, and carbon
NPs [8,9]. For GBM, siRNA targeting MGMT (O6-methylguanine methyltransferase, a key factor in
brain tumor resistance to TMZ) delivered by iron oxide NPs conjugated with chlorotoxin could enhance
temozolomide (TMZ) toxicity [10]. Polyethyleneimine (PEI)-entrapped gold NP modified with an
arginine-glycine-aspartic peptide was capable of delivering siRNA targeting Bcl-2 to GBM cells to
increase cell apoptosis [11]. In our previous studies, a type of cationic PEI-coated Fe3O4 NPs were
proved to be effective in siRNA protection and siRNA delivery into mesenchymal stem cells [12].
The capacity of PEI-coated Fe3O4 NPs to deliver siRNA into GBM cells for gene silencing was unknown.
Repressor element 1-silencing transcription factor (REST, also named NRSF and XBR) is a
zinc-finger transcription factor belong to krüppel family, it binds to a specific DNA motif (repressor
element 1) within regulatory regions to repress gene transcription [13]. We demonstrated in our
previous study that REST could work as a master regulator which maintains cell proliferation and
migration in GBM cells, which might represent a potential target for GBM therapy [14]. In the present
study, we aimed to investigate the PEI-coated Fe3O4 NPs for the delivery of therapeutic siRNA
targeting REST into GBM cells, providing a novel treatment strategy for GBM.
2. Results
2.1. Characterization of Polyethyleneimine (PEI)-Coated Fe3O4 Nanoparticles (NPs)
The prepared PEI-coated Fe3O4 NPs were water soluble and characterized by transmission
electron microscope (TEM), dynamic light scattering (DLS) and magnetometer. In the TEM image
of the PEI-coated Fe3O4 NPs, the morphology of the NPs was compact and close to spherical, with
a diameter of about 14 nm, which was the same as Fe3O4 NPs without PEI coating (Figure 1A–D).
However, it was difficult to observe the PEI coating on the NPs directly by TEM, due to the transparence
of PEI under TEM. Subsequently, the PEI-coated Fe3O4 NPs were analyzed by DLS, it showed the
hydrodynamic size of 18.21 nm and the zeta potential of 25.7 mV, indicating the small hydrodynamic
size and positive net charge of the NPs (Figure 1F). While the results of NPs without PEI coating showed
the hydrodynamic size of 21.83 nm and the zeta potential of −41.4 mV (Figure 1E). The magnetization
curve of the Fe3O4 NPs was given in Figure 1G,H. The curve does not show any hysteresis loop
which is characteristic for superparamagnetic Fe3O4 NPs. The saturation magnetization is obtained as
47.0 emu/g for the NPs and 42.5 emu/g for the NPs without PEI. In addition, the binding efficiency of
PEI on magnetic nanoparticles (MNPs) was analyzed by thermogravimetric analysis, and it was found
that the binding of PEI on MNP was 18% (Figure 1I,J).
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Figure 1. Characterization of the polyethyleneimine (PEI)-coated Fe3O4 NPs. (A) The transmission electron 
microscope (TEM) image of the Fe3O4 NPs without PEI. Scale bar indicates 50 nm; (B) the particle size 
distribution of the Fe3O4 NPs without PEI, from the analysis of TEM images; (C) the TEM image of the PEI-
coated Fe3O4 NPs. Scale bar indicates 50 nm; (D) the particle size distribution of the PEI-coated Fe3O4 NPs, 
from the analysis of TEM images; (E) the hydrodynamic size of the Fe3O4 NPs without PEI, analyzed by 
dynamic light scattering (DLS). (F) the hydrodynamic size of the PEI-coated Fe3O4 NPs, analyzed by DLS; 
(G) The magnetization curve of the Fe3O4 NPs without PEI was analyzed by magnetization curve obtained 
by vibrating sample magnetometer (VSM) at room temperature; (H) The magnetization curve of the PEI-
coated Fe3O4 NPs was analyzed by magnetization curve obtained by vibrating sample magnetometer 
(VSM) at room temperature; (I) the thermogravimetric analysis curve of the Fe3O4 NPs without PEI; (J) the 
thermogravimetric analysis curve of the PEI-coated Fe3O4 NPs. 
Figure 1. Characterizatio f the polyethyleneimine (PEI)-coated Fe3O4 NPs. (A) The tra smission
electron microscope (TEM) image of the Fe3O4 NPs without PEI. Scale bar indicates 50 nm; (B) the particle
size distribution of the Fe3O4 NPs without PEI, from the analysis of TEM images; (C) the TEM image of the
PEI-coated Fe3O4 NPs. Scale bar indicates 50 nm; (D) the particle size distribution of the PEI-coated Fe3O4
NPs, from the analysis of TEM images; (E) the hydrodynamic size of the Fe3O4 NPs without PEI, analyzed
by dynamic light scattering (DLS). (F) the hydrodynamic size of the PEI-coated Fe3O4 NPs, analyzed
by DLS; (G) The magnetization curve of the Fe3O4 NPs without PEI was analyzed by magnetization
curve obtained by vibrating sample magnetometer (VSM) at room temperature; (H) The magnetization
curve of the PEI-coated Fe3O4 NPs was analyzed by magnetization curve obtained by vibrating sample
magnetometer (VSM) at room temperature; (I) the thermogravimetric analysis curve of the Fe3O4 NPs
without PEI; (J) the thermogravimetric analysis curve of the PEI-coated Fe3O4 NPs.
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2.2. Interaction between the NP and siRNA
For achieving siRNA delivery, the delivery reagents are required to form complexes with siRNA
in vitro. Here, the capacity of the PEI-coated Fe3O4 NPs to interact with siRNA was examined by gel
retardation assay. As shown in Figure 2A,B, the observed siRNA was reduced in a ratio-dependent
manner when incubated with the PEI-coated Fe3O4 NPs and almost completely retarded at a weight
ratio of 2.8:1. It is suggested that the PEI-coated Fe3O4 NPs could form complexes with siRNA to block
siRNA migration in the agarose gel electrophoresis, and the interaction proportion of NP to siRNA
was 2.8:1. In addition, the size of the siRNA-loaded NPs has been determined to be 43.56 nm by DLS
when the ratio of NPs/siRNA was 4, which proved the stability of the NP/siRNA complexes.
Int. J. Mol. Sci. 2018, 19, x FOR PEER REVIEW  4 of 11 
 
2.2. Interaction between the NP and siRNA 
For achieving siRNA delivery, the delivery reagents are required to form complexes with siRNA 
in vitro. Here, the capacity of the PEI-coated Fe3O4 NPs to interact with siRNA was examined by gel 
retardation assay. As shown in Figure 2A,B, the observed siRNA was reduced in a ratio-dependent 
manner when incubated with the PEI-coated Fe3O4 NPs and almost completely retarded at a weight 
ratio of 2.8:1. It is suggested that the PEI-coated Fe3O4 NPs could form complexes with siRNA to block 
siRNA migration in the agarose gel electrophoresis, and the interaction proportion of NP to siRNA 
was 2.8:1. In addition, the size of the siRNA-loaded NPs has been determined to be 43.56 nm by DLS 
when the ratio of NPs/siRNA was 4, ic  r ved the stability of the NP/siRNA complexes. 
 
Figure 2. The cellular uptake of the NP/siRNA complexes in U-87 cells. (A) The interaction of the PEI-
coated Fe3O4 NPs with siRNA at different NP/siRNA weight ratios, analyzed by gel retardation assay; 
(B) the gray value analysis for the results of gel retardation assay. * p < 0.05 compared with the 0 
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Figure 2. The cellular upta the NP/siRNA complexes in U-87 cells. (A) The i teraction of the
PEI-coated Fe3 4 NPs with siRNA at different NP/siRNA weight ratios, analyzed by gel retardation assay;
(B) the gray value analysis for the results of gel retardation assay. * p < 0.05 compared with the 0 group;
(C) the cellular uptake of the NP/siRNA complexes in U-87 cells was verified by prussian blue staining,
fluorescence labeling and flow cytometry, P2 presented positive proportions. Bar indicates 100 µm.
2.3. Cellular Uptake of the NP/siRNA Complexes
To verify the siRNA delivery into GBM cells by the PEI-coated Fe3O4 NPs, two human GBM cell
lines U-87 and U251 cells were used. The cells were incubated with NP/siRNA complexes at the ratio
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of 0, 2, 4, 6 and 8 for 6 h, respectively. The cellular uptakes of the NPs stained with prussian blue are
shown in Figures 2C and 3. It was observed that almost all the cells were stained blue and darker when
the NP/siRNA ratio was 4 or 6. Furthermore, 5-Carboxyfluorescein (FAM)-conjunct siRNA was used
to analyze the cellular uptake of siRNA delivered by the NPs. Under the fluorescence microscope, the
fluorescence labeling of siRNA was observed, indicating the cellular uptake of the siRNA. The labeling
efficiencies were detected using flow cytometry and it showed a NP/siRNA ratio-dependent behavior.
Nevertheless, the efficiencies detected by flow cytometry were lower than the results of prussian blue
staining and fluorescence labeling. This could be due to the detection sensitivity and the quenching of
fluorescein by NP. These results indicated efficient delivery of siRNA in to GBM cells by the PEI-coated
Fe3O4 NPs.
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2.4. ( epres or Element 1-Silencing Transcription Factor) Silencing Mediated by NP/siRNA Complexes
To verify the gene silencing mediated by NP/siRNA complexes in GBM cells, the cells were
incubated with NP/siRNA complex s at the ratio of 4 for 24 h, real-time polymerase c ain reaction
(PCR) an Western blotting were carried out. As shown in Figur 4A, the mRNA levels of REST i
U-87 and U-251 cells treated ith NP/siRNA targeting REST was significantly reduced as compared
to control experiments. Consistent with the trend of realtime PCR results, West rn blotting showe
stronger REST knockdown i U-87 and U-251 c lls (Figure 4B,C), indicating that REST was silenced by
NP/siRNA complexes mainly in transcription and translation levels.
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Figure 4. Repr ssor elem nt 1-silencing transcription factor (REST) silencing mediated by NP/siRNA
complexes in GBM cells. (A) The mRNA levels of REST in U-87 and U-251 cells incubated with
NP/siRNA complex s (at the ratio of 4 h for 24 h) targeting REST, ass yed by real-time polymerase
chain reaction (PCR); (B) The protein levels in U-87 cells trea ed with NP/siRNA complexes targeting
REST were detected by Western blotting; (C) The protein levels in U-251 cells trea ed with NP/siRNA
complexes targeting REST wer detected by estern * p < 0.05 compared with the
contr l group.
2.5. Anti-Tumor Activi y of NP/siRNA Complexes
Cell viab lity and migration are cru ial to GBM development and metastasis. The anti-tumor
activi y of REST-silenci g mediated by the PEI-coated Fe3O4 NPs was determined using CCK-8 ass y
and transwell ass y in U-87 and U-251 GBM cells. In the c ll viability ass y, the conce tration f the
NP/siRNA was 200 ng/50 ng. In Figure 5A,B, the r sults of the CCK-8 ass y present d significant
reduction f the cell viabilities upon siRNA against REST delivery by the PEI-coated Fe3O4 NPs, both in
U-87 and U-251 cells. Moreover, th cell migration capacities of U-87 and U-251 cells were significantly
inhibited by the NP/siRNA complexes targeting REST (Figure 5C,D). These data have proved the
PEI-c ate Fe3O4 NPs as a novel delivery system for siRNA into GBM cells, and the combination with
siRNA for REST provided a novel promising potential st ategy for GBM treatment.
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3. Discus ion
In recent years, studies on the molecular mechanisms of GBM oc urrence, development and
drug resistance have provided a lot of potential therapeutic targets, but they have not significantly
promoted the progres of clinical treatment. The siRNA-based ap roaches make it pos ible for any
abnormal highly expres ed genes to be silenced, including undrug able genes. Nanomaterials have
opened novel op ortunities for the delivery of therapeutic molecules which cannot be readily taken up,
s ch as siRNA [8]. The siRNA is a double-stranded RNA with typically 21– 3 nucleotides having 3′
two-nucleotide ov rhangs [6]. Its negative charge llows the use of th cationi carriers including lipids,
dendrimers, natu al polymers and PEI [15]. Recently, lipopo ymetric NP, PEI-functionalized gold
nanorods and PEI NP have been reported in th NP/siRNA-based therapy strategie for GBM [16–19].
In a similar approach, we managed to produce PEI-c ated Fe3O4 NP/siRNA complexes for its targ ted
delive y. The z ta potential of the PEI-coated F 3O4 NP was measured as +25.7 mV and the net charge
was reduced after forming complexes with negativ ly charged siRNA,. This could still facilitate the
approaching of NP to a negatively charged cell membrane to promote NP/siRNA cellular uptake.
The excessive siRNA could neutraliz the net c arge of the NP/siRNA complexes and reduc the
cellular ptake, while excessive NP exc ed d the c llu ar uptake ability and epressed the siRNA
delivery. Therefore, the balance betwe n the efficiency of NP cellular uptake and the efficiency of
siRNA delivery has be n considered in the optimization of delivery strategies. The gene-silencing
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efficiency achieved 30% when the weight ratio of NP/siRNA was 4. In addition, during the preparation
of NP/siRNA complexes, the NP and siRNA were diluted separately followed by mixing evenly to
prevent the aggregation of the complexes for maintaining a high transfection efficiency.
Furthermore, it is crucial to select appropriate target genes. Target gene candidates in cancer
therapy are mainly involved in oncogenes, angiogenesis and proliferation, like PLK1, EphA2, RRM2,
KRAS, PKN3 and VEGF, which have been tested as target genes in early-phase clinical trials for
RNAi-based cancer therapies [7]. For GBM, mostly studied target genes of siRNA included oncogenes,
cytokine receptors and key signaling regulators, such as BCL2, SIRT2, GAL1, c-Met, EGFR, BAG3 and
PLK1 [8]. Nevertheless, most of these target genes are not cancer-specific, and may lead to side effects
like chemotherapy. According to the previous studies, REST was a transcriptional repressor against
neuron-specific genes in non-neuronal cells. It also acts as a tumor suppressor in non-neural tumors
while as an oncogene in neural tumors [13,20]. Therefore, REST is a specific target for treatment of GBM
along with the potential to repair nerve injury by promoting neuron differentiation. Here, we have
analyzed the two most important factors in cancer development; proliferation and migration, after
the delivery of the REST siRNA via PEI-coated Fe3O4 NP into GBM cells. The cell viability showed
that the cell proliferation decreased, and the cell migration ability decreased to 50% by transwell assay.
These results suggest that the delivery of REST siRNA via the NPs to GBM cells can effectively reduce
proliferation and migration ability, providing a new way for gene therapy against GBM.
In summary, we demonstrated the use of PEI-coated Fe3O4 NP as a delivery system for therapeutic
siRNA delivery. We found out the appropriate NP/siRNA weight ratio for the REST silencing in GBM
cells, inhibiting cell proliferation and migration efficiently. These findings represent a novel potential
treatment strategy for GBM.
4. Materials and Methods
4.1. Synthesis of PEI-Coated Fe3O4 NPs
The preparation of PEI-coated Fe3O4 NPs was carried out according to the previous
reports [12,21,22]. Briefly, oleic acid-capped Fe3O4 NPs were synthesized and oleic acid was replaced
by meso-2,3-dimercaptosuccinic acid. The meso-2,3-dimercaptosuccinic acid-capped Fe3O4 NPs were
collected by magnetic separation and dissolved in deionized water. The NPs (0.175 ng/mL, 20 mL)
were added into PEI solution (0.5 mg/mL, 20 mL) under stirring, sonicated for 20 min and stirred for
2 h. Ultrafiltration was applied for the removal of free PEI to get PEI-Coated Fe3O4 NPs.
4.2. NPs Characterization
The PEI-coated Fe3O4 NPs were characterized by transmission electronic microscopy (TEM,
JEM-2100, JEOL Ltd., Tokyo, Japan) at 120 kV and the particle size was analyzed using ImageJ
software (NIH, Bethesda, MD, USA) where the samples were prepared as described in literature [23].
DLS was carried out for the analysis of hydrodynamic size and zeta potential using Zetasizer 3000HS
(Malvern Instruments Ltd., Worcestershire, UK). The thermogravimetric analysis was performed using
thermogravimetric analyzer (TG 209 F3, NETZSCH, Shanghai, China).
4.3. Gel Retardation Assay
1 µg siRNA NC (5′-UCCGAACGUGUCACGUTT-3′, non-targeting siRNA, synthesized by
GenePharma, Shanghai, China) was mixed with 0, 0.6, 1.2, 1.8, 2.4, 2.6 and 2.8 µg PEI-coated
Fe3O4 NPs to get NPs/siRNA weight ratio of 0, 0.6, 1.2, 1.8, 2.4, 2.6 and 2.8, siRNA and NPs were
diluted with Opti-MEM I Reduced Serum Medium (Gibco, Shanghai, China) to 10 µL before mixture.
The final volume of each mixture was 20 µL and they were incubated at room temperature for 5 min.
Electrophoresis was carried out using 2% agarose gel at 100 V for 20 min. The siRNA bands were
visualized by DuRed (Fanbo, Beijing, China) and imaged using a Tanon-1600 image analysis system
(Tanon, Shanghai, China). The gray value of the image was analyzed by ImageJ.
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4.4. Cell Culture
The human GBM cell lines U-87 and U-251 were obtained from the Cell Bank of the Chinese
Academy of Sciences (Shanghai, China). These two cells were incubated in Dulbecco’s Modified
Eagle Medium (DMEM, HyClone, Beijing, China) culture medium, supplemented with 10% fetal
bovine serum (FBS, HyClone) and 1% Penicillin streptomycin (Gibco, Shanghai, China) at 37 ◦C in a
humidified atmosphere containing 5% CO2 [14].
4.5. Transfection of siRNA
The cells were seeded in 6-well plates and incubated as described above for 12 h before transfection.
1 µg siRNA NC, siREST (5′-GCUGCGGCUACAAUACUAATT-3′) and FAM-siRNA NC (FAM-conjunct
siRNA NC for fluorescence detections) were diluted with 100 µL Opti-MEM I Reduced Serum Medium
separately; 0, 2, 4, 6 and 8 µg PEI-coated Fe3O4 NPs were also diluted with 100 µL Opti-MEM I
Reduced Serum Medium separately; The diluted siRNA was added to the diluted NPs respectively
and incubated at room temperature for 5 min. Then the mixtures were added to the cells and cultured
for the indicated time. All the siRNA duplexes were chemically synthesized by GenePharma. 6 h after
transfection with FAM-siRNA NC, the cells were observed under a fluorescence microscope Observer
A1 (Carl Zeiss, Oberkochen, Germany) and the transfection efficiencies were detected using a flow
cytometry (BD Biosciences, Franklin Lakes, NJ, USA).
4.6. Prussian Blue Staining
The cells were seeded and indubated in 6-well plates. The transfection with NP/siRNA complexes
was carried out and cultured for 6 h. Then, 4% paraformaldehyde was used to fix the cells for 30 min.
The cells were rinsed with phosphate buffer saline (PBS) and stained with 1 mL of 2% potassium
ferrocyanide in 6% hydrochloric acid (Perl reagent for Prussian blue staining) for 30 min. The cells
were washed and the iron uptake was observed by a light microcopy (CKX31, Olympus, Tokyo, Japan).
4.7. RNA Extraction and Realtime Polymerase Chain Reaction (PCR) Assay
Total RNA was extracted from cells using RNAiso Plus (Takara, Dalian, China) and quantified
using NanoDrop 2000C spectrophotometer (Thermo, Wilmington, DE, USA). The PrimeScript RT
reagent Kit with gDNA Eraser purchased from Takara was used for the reverse transcription. The SYBR
Premix Ex Taq II from Takara was used for the quantitative real-time PCR. PCR was performed on ABI
7500 Real-Time PCR System. The mRNA levels of genes were calculated using the 2−∆∆Ct method.
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was served as an internal control. The primers
were chemically synthesized by AuGCT Biotech (Beijing, China). The sequences are as following
(Table 1).
Table 1. Primer sequences for real-time PCR.
Gene Primer Sequence Product Lengths (bp)
REST Forward: 5
′-CGCCCATATAAATGTGAACTTTGTC-3′
Reverse: 5′-GGCGGGTTACTTCATGTTGATTAG-3′ 145
GAPDH Forward: 5
′-GCACCGTCAAGGCTGAGAAC-3′
Reverse: 5′-TGGTGAAGACGCCAGTGGA-3′ 138
4.8. Protein Extraction and Western Blotting
Total protein samples were extracted by RIPA lysis buffer (Beyotime, Haimen, China) and
quantified by BCA protein assay kit (Takara). The protein samples were loaded and separated by
10% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to PVDF
membrane (Millipore, Beijing, China). The membrane was incubated in diluted primary antibodies
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against REST (1:1000, Santa Cruz, Dallas, TX, USA) and GAPDH (1:5000, Proteintech, Wuhan, China)
overnight at 4 ◦C. After probing with horseradish peroxidase (HRP)-conjugated secondary antibodies
(Proteintech) at room temperature for 1 h, protein bands were visualized using Clarity Western
ECL Substrate (Bio-Rad, Hercules, CA, USA) on a chemiluminescence detection system (Tanon 5200,
Shanghai, China). The protein bands were analyzed using ImageJ.
4.9. Cell Viability Assay
The cell viabilities were assessed by cell counting kit-8 (CCK-8, Dojindo, Shanghai, China)
according to the manufacturer’s instructions. The cells were seeded in 96-well plates, transfected with
NP/siRNA complexes and cultured for 24 h. 10 µL CCK-8 reagent was added and incubated at 37 ◦C
for 1 h. The absorbance at 450 nm was detected using iMARK microplate reader (Bio-Rad, Hercules,
CA, USA).
4.10. Transwell Assay
Transwell chambers with 8 µm pores (6.5 mm diameter, Corning, Tewksbury, MA, USA) were
used for the transwell assays. The cells were seeded into the upper chambers in serum-free culture
medium and complete medium was added into the lower chamber. After 12 h culture, the cells on the
upper surface of the membrane were carefully removed using cotton swabs and the membrane with
cells were fixed with methanol and stained with 4′,6-diamidino-2-phenylindole (DAPI, Sigma-Aldrich,
Shanghai, China). The images were obtained using an Observer A1 microscope.
4.11. Statistical Analysis
The data was presented as the mean ± standard deviation (SD). One-way analysis of variance
(ANOVA) followed by Tukey’s post hoc test was carried out for the statistical analyses, using
GraphPad Prism 6 software (GraphPad Software, Inc., La Jolla, CA, USA). * p < 0.05 was considered
statistically significant.
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